panaxadiol has been researched along with Colonic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, CG; Jin, CH; Jin, HL; Jin, X; Li, MY; Ma, J; Piao, LX; Ri, M; Wang, JY; Wang, Z; Xing, Y; Xu, GH; Zhang, ZH; Zuo, HX | 1 |
| Cao, MN; Guo, DA; He, WN; Lin, XH; Ye, M; Yu, SW | 1 |
2 other study(ies) available for panaxadiol and Colonic Neoplasms
| Article | Year |
|---|---|
Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Line; Cell Proliferation; Colonic Neoplasms; Ginsenosides; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Mice, Nude; STAT3 Transcription Factor; T-Lymphocytes | 2020 |
Biotransformation of 20(R)-panaxadiol by the fungus Rhizopus chinensis.
Topics: Antineoplastic Agents; Biotransformation; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fungi; Ginsenosides; Humans; Hydroxylation; Lipopolysaccharides; Luciferases; Molecular Structure; NF-kappa B; Nuclear Magnetic Resonance, Biomolecular; Rhizopus; Stereoisomerism | 2014 |